Harpoon Therapeutics - HARP Stock Forecast, Price & News

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Harpoon Therapeutics Stock Performance

NASDAQ:HARP opened at $2.16 on Tuesday. Harpoon Therapeutics has a 1 year low of $1.73 and a 1 year high of $10.60. The company has a fifty day moving average of $2.19 and a two-hundred day moving average of $3.32.

Harpoon Therapeutics (NASDAQ:HARP - Get Rating) last announced its quarterly earnings results on Thursday, May 12th. The company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.14). Harpoon Therapeutics had a negative net margin of 366.46% and a negative return on equity of 112.69%. The company had revenue of $5.91 million during the quarter, compared to analyst estimates of $11.31 million. As a group, analysts predict that Harpoon Therapeutics will post -2.17 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on HARP shares. Piper Sandler lowered their price objective on shares of Harpoon Therapeutics from $14.00 to $9.00 in a report on Friday, May 27th. Wedbush increased their target price on Harpoon Therapeutics from $5.00 to $7.00 and gave the stock an "outperform" rating in a report on Monday, May 16th. Roth Capital raised their target price on Harpoon Therapeutics from $14.00 to $18.00 in a research report on Tuesday, May 17th. Cantor Fitzgerald restated an "overweight" rating on shares of Harpoon Therapeutics in a research note on Monday, May 9th. Finally, Canaccord Genuity Group reissued a "buy" rating and set a $16.00 price objective on shares of Harpoon Therapeutics in a report on Wednesday, July 6th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $12.89.